FC
AMLX icon

Financial Consulate’s Amylyx Pharmaceuticals AMLX Stock Holding History

Financial Consulate’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25
Closed -$302 – 1403
2025
Q4 		$302 Hold
25
– – ﹤0.01% 1273
2025
Q3 		$340 Buy
+25
New +$235 ﹤0.01% 1103

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Financial Consulate's AMLX Position: Q1 2026 in Review

Financial Consulate sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 25 shares — an estimated $302 sold.

Financial Consulate first reported a position in AMLX in Q3 2025 and held it in 2 quarters. The position peaked at $340 in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Financial Consulate reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Financial Consulate sold 25 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $302.
  • Financial Consulate first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Financial Consulate's Amylyx Pharmaceuticals position peaked at $340 in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.